Simone Villa

Dr. Simone Villa

StopTB Italia Onlus
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2020 in Pulmonology
Verified
Journal Article
Open access
IMI. Motta
I. Motta
RCR. Centis
R. Centis
LDL. D’aMbrosio
L. D’aMbrosio
JGJosé-María García-García
José-María García-García
DGD. Goletti
D. Goletti
GMGiovanni Battista Migliori
Giovanni Battista Migliori
Little is known about the relationship between the COVID-19 and tuberculosis (TB). The aim of this study is to describe a group of patients who died with TB (active disease or sequelae) and COVID-19 in two cohorts. Data from 49 consecutive cases in 8 countries (cohort A) and 20 hospitalised patients with TB and COVID-19 (cohort B) were analysed and patients who died were described. Demographic and clinical variables were retrospectively collected, including co-morbidities and risk factors for TB and COVID-19 mortality. Overall, 8 out of 69 (11.6%) patients died, 7 from cohort A (14.3%) and one from cohort B (5%). Out of 69 patients 43 were migrants, 26/49 (53.1%) in cohort A and 17/20 (85.0%) in cohort B. Migrants: (1) were younger than natives; in cohort A the median (IQR) age was 40 (27-49) VS. 66 (46-70) years, whereas in cohort B 37 (27-46) VS. 48 (47-60) years; (2) had a lower mortality rate than natives (1/43, 2.3% versus 7/26, 26.9%; p-value: 0.002); (3) had fewer co-morbidities than natives (23/43, 53.5% versus 5/26-19.2%) natives; p-value: 0.005). The study findings show that: (1) mortality is likely to occur in elderly patients with co-morbidities; (2) TB might not be a major determinant of mortality and (3) migrants had lower mortality, probably because of their younger age and lower number of co-morbidities. However, in settings where advanced forms of TB frequently occur and are caused by drug-resistant strains of M. tuberculosis, higher mortality rates can be expected in young individuals.

1 June 2020 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
CSClaudia Stochino
Claudia Stochino
SVSimone Villa
Simone Villa
PZPatrizia Zucchi
Patrizia Zucchi
PPPierpaolo Parravicini
Pierpaolo Parravicini
AGAndrea Gori
Andrea Gori
Mario C. RaviglioneMario C. Raviglione
Mario C. Raviglione
The COVID-19 infection rate was high in patient with active tuberculosis. Major clinical complications were seen only in two patients thus requiring ex novo oxygen supply, one of whom with advanced tuberculosis died. Nasal swab viral clearance was rapid.

1 November 2020 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
SVSimone Villa
Simone Villa
EJErnesto Jaramillo
Ernesto Jaramillo
DMDavide Mangioni
Davide Mangioni
ABAlessandra Bandera
Alessandra Bandera
AGAndrea Gori
Andrea Gori
MRMario Carlo Raviglione
Mario Carlo Raviglione

28 November 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
Andrea LombardiAndrea Lombardi
Andrea Lombardi
SVSimone Villa
Simone Villa
VCValeria Castelli
Valeria Castelli
ABAlessandra Bandera
Alessandra Bandera
AGAndrea Gori
Andrea Gori
Immune exhaustion is a condition associated with chronic infections and cancers, characterized by the inability of antigen-specific T cells to eliminate the cognate antigen. Exhausted T cells display a peculiar phenotypic profile and exclusive functional characteristics. Immune exhaustion has been described in patients with Mycobacterium tuberculosis infection, and cases of tuberculosis reactivation have been reported in those treated with immune checkpoint inhibitors, drugs able to re-establish T-cells’ function. Exhausted T CD8+ cells’ profile has also been described in patients with infection due to nontuberculous mycobacteria. In this review, we initially provide an overview of the mechanisms leading to immune exhaustion in patients infected by Mycobacterium tuberculosis and nontuberculous mycobacteria. We then dissect the therapeutic perspectives related to immune checkpoint blockade in patients with these infections.

30 April 2020 in Global Health & Medicine
Verified
Journal Article
Closed access
PDF file
SVSimone Villa
Simone Villa
Andrea LombardiAndrea Lombardi
Andrea Lombardi
DMDavide Mangioni
Davide Mangioni
GBGiorgio Bozzi
Giorgio Bozzi
ABAlessandra Bandera
Alessandra Bandera
MRMario C. Raviglione
Mario C. Raviglione
COVID-19, that emerged in December 2019 in the city of Wuhan, China and is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly evolved into a pandemic. Italy has become one of the largest epicentres outside Asia, accounting now for at least 80,539 infections (cumulative incidence of 95.9/100,000) and 8,165 deaths (case fatality rate 10.1%). It has seriously affected people above the age of 60 years. The International Health Regulations (IHR) revised in 2005 bind governments to disclose vital information regarding the identification and detection of new disease outbreaks regardless of its causative agent. In contrast to the previous SARS epidemic, China timely informed the world about the onset of a new outbreak. It also soon disclosed the clinical characteristics of patients with COVID-19. Unfortunately, despite the fast recognition of the Chinese epidemic, the application of the 2005 IHR was not followed by an effective response in every country and most health authorities failed to rapidly perceive the threat posed by COVID-19. To further complicate matters, IHR implementation, which relies primarily on self-reporting data rather than on an external review mechanism, was limited in speed and further hindered by high costs. The response in Italy suffered from several limitations within the health system and services. The action against this threat must instead be quick, firm and at the highest trans-national level. The solution lies in further strengthening countries' preparedness through a clear political commitment, mobilization of proper resources and implementation of a strict surveillance and monitoring process.

14 August 2019 in European Respiratory Journal
Verified
Journal Article
Closed access
SVSimone Villa
Simone Villa
LCLuigi Codecasa
Luigi Codecasa
MFMarino Faccini
Marino Faccini
MPMirella Maria Pontello
Mirella Maria Pontello
MFMaurizio Ferrarese
Maurizio Ferrarese
Mario C. RaviglioneMario C. Raviglione
Mario C. Raviglione
In countries of the European Union, tuberculosis (TB) mainly affects marginalised people, including asylum seekers. Migratory flows from high-incidence countries to Italy have increased up to 2017, posing challenges to the national health system. This study sought to assess TB and latent TB infection (LTBI) prevalence among asylum seekers in Milan during the biennium 2016–2017 and to evaluate interventions in place.A two-level active surveillance and screening system was developed for both TB and LTBI. Asylum seekers underwent an initial screening with a tuberculin skin test (TST) and a questionnaire at the receiving sites. At the Regional TB Reference Centre, those with a positive result underwent chest radiography. People aged <35 years with negative chest radiography results underwent further testing by interferon-γ release assay. If results of the assay were positive, LTBI treatment was offered. TB and LTBI prevalence were compared with literature data.A total of 5324 asylum seekers, mostly young (10–39 years; 98%), male (84%) and from sub-Saharan Africa (69%), were enrolled in the study. 69 active TB cases were diagnosed and 863 LTBI-positive individuals were detected. TB prevalence was high (1236 per 100 000 population) and LTBI prevalence was 28%. Despite losses (41%) during the transition from initial screening sites and the diagnostic centre, a good TB cure rate (84%) and optimal LTBI treatment completion (94%) were achieved.Our study shows that TB incidence is high among asylum seekers in Milan and that well-coordinated screening measures are critical for early diagnosis and treatment. It also proves that rolling out successful at-scale interventions for both prophylaxis and disease management is feasible.